secwatch / observer
8-K filed March 3, 2023, 6:59 PM ET ticker QNCX CIK 0001662774
leadership confidence high sentiment neutral materiality 0.55

Quince Therapeutics appoints Brendan Hannah as principal financial officer after Ted Monohon resigns

Quince Therapeutics, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ted Monohon

Chief Accounting Officer and Vice President of Finance
QNCX · Quince Therapeutics, Inc.
Effective
2023-03-16
Successor
Brendan Hannah
Filed
March 3, 2023, 6:59 PM ET
On March 1, 2023, Ted Monohon informed Quince Therapeutics, Inc. (the “ Company ”) of his intention to resign from his position as the Chief Accounting Officer and Vice President of Finance, including as the principal financial officer and principal accounting officer, effective as of March 16, 2023.
Appointed

Brendan Hannah

principal financial officer and principal accounting officer
QNCX · Quince Therapeutics, Inc.
Effective
2023-03-16
Filed
March 3, 2023, 6:59 PM ET
On March 3, 2023, the Board of Directors of the Company appointed Brendan Hannah, Chief Business Officer of the Company, as the Company’s principal financial officer and principal accounting officer, effective as of March 16, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ted Monohon resigned as Chief Accounting Officer and Vice President of Finance at Quince Therapeutics, Inc..

Action
resigned
Role
Chief Accounting Officer and Vice President of Finance
Exact text from the filing
On March 1, 2023, Ted Monohon informed Quince Therapeutics, Inc. (the “ Company ”) of his intention to resign from his position as the Chief Accounting Officer and Vice President of Finance, including as the principal financial officer and principal accounting officer, effective as of March 16, 2023.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Brendan Hannah was appointed as principal financial officer and principal accounting officer at Quince Therapeutics, Inc..

Action
appointed
Role
principal financial officer and principal accounting officer
Exact text from the filing
On March 3, 2023, the Board of Directors of the Company appointed Brendan Hannah, Chief Business Officer of the Company, as the Company’s principal financial officer and principal accounting officer, effective as of March 16, 2023.
View on SEC.gov

Quince Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-23-060044
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.